Next report date
Report period
Q1 2024
EPS estimate
−0.44USD
Revenue estimate
5.98 MUSD
−1.42USD
−54.81 MUSD
13.59 MUSD
29.08 M
About scPharmaceuticals Inc.
Sector
CEO
John H. Tucker
Headquarters
Burlington
Website
Employees (FY)
136
Founded
2013
FIGI
BBG00J24RT13
scPharmaceuticals, Inc. engages in the development of transformative pharmaceutical products for subcutaneous delivery. Its products include FUROSCIX, a furosemide injection which is used as parenteral diuretic in treating heart failure and scCeftriaxone, used as parenteral antibiotic outside the hospital setting. The company was founded by Pieter Muntendam and Bertram Pitt in February 2013 and is headquartered in Burlington, MA.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of SCPH is 4.50 USD — it has decreased by 2.39% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange scPharmaceuticals Inc. stocks are traded under the ticker SCPH.
scPharmaceuticals Inc. is going to release the next earnings report on May 8, 2024. Keep track of upcoming events with our Earnings Calendar.
SCPH stock is 5.79% volatile and has beta coefficient of 0.49. Check out the list of the most volatile stocks — is scPharmaceuticals Inc. there?
SCPH earnings for the last quarter are −0.41 USD per share, whereas the estimation was −0.37 USD resulting in a −12.33% surprise. The estimated earnings for the next quarter are −0.42 USD per share. See more details about scPharmaceuticals Inc. earnings.
scPharmaceuticals Inc. revenue for the last quarter amounts to 3.80 M USD despite the estimated figure of 3.40 M USD. In the next quarter revenue is expected to reach 5.52 M USD.
Yes, you can track scPharmaceuticals Inc. financials in yearly and quarterly reports right on TradingView.
SCPH stock has fallen by 4.05% compared to the previous week, the month change is a 11.94% fall, over the last year scPharmaceuticals Inc. has showed a 55.36% decrease.
SCPH net income for the last quarter is −13.81 M USD, while the quarter before that showed −15.63 M USD of net income which accounts for 11.65% change. Track more scPharmaceuticals Inc. financial stats to get the full picture.
Today scPharmaceuticals Inc. has the market capitalization of 162.25 M, it has decreased by 2.14% over the last week.
No, SCPH doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, SCPH shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade scPharmaceuticals Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 25, 2024, the company has 136.00 employees. See our rating of the largest employees — is scPharmaceuticals Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So scPharmaceuticals Inc. technincal analysis shows the strong sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating scPharmaceuticals Inc. stock shows the strong sell signal. See more of scPharmaceuticals Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on scPharmaceuticals Inc. future price: according to them, SCPH price has a max estimate of 25.00 USD and a min estimate of 16.00 USD. Read a more detailed scPharmaceuticals Inc. forecast: see what analysts think of scPharmaceuticals Inc. and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. scPharmaceuticals Inc. EBITDA is −54.77 M USD, and current EBITDA margin is −402.93%. See more stats in scPharmaceuticals Inc. financial statements.